JACOB MANDEL to Clinical Trials as Topic
This is a "connection" page, showing publications JACOB MANDEL has written about Clinical Trials as Topic.
Connection Strength
0.719
-
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
Score: 0.426
-
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
Score: 0.095
-
Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605.
Score: 0.084
-
Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr; 16(4):380.
Score: 0.082
-
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. J Geriatr Oncol. 2020 04; 11(3):451-454.
Score: 0.030